biostudies-literatureLi LNIAID NIH HHSNIH HHS63https://www.ebi.ac.uk/biostudies/studies/S-EPMC9113379biostudies-literatureUnknown12(1)<h4>Background</h4>Neutralizing antibodies are approved drugs to treat coronavirus disease-2019 (COVID-19) patients, yet mutations in severe acute respiratory syndrome coronavirus (SARS-CoV-2) variants may reduce the antibody neutralizing activity. New monoclonal antibodies (mAbs) and antibody remolding strategies are recalled in the battle with COVID-19 epidemic.<h4>Results</h4>We identified multiple mAbs from antibody phage display library made from COVID-19 patients and further characterized the R3P1-E4 clone, which effectively suppressed SARS-CoV-2 infection and rescued the lethal phenotype in mice infected with SARS-CoV-2. Crystal structural analysis not only explained why R3P1-E4 had selectively reduced binding and neutralizing activity to SARS-CoV-2 variants carrying K417 mutations,Cell & bioscienceAntibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants.PMC9113379AI158154R01AI069120AI140718R01 AI140718Deng YQDuan JYang HLi JZu SGuo YJiao PRao ZAliyari SRLi LShi YGao MCao YCheng GWan DQin CFfalseAntibody engineering improves neutralization activity against K417 spike mutant SARS-CoV-2 variants.<h4>Background</h4>Neutralizing antibodies are approved drugs to treat coronavirus disease-2019 (COVID-19) patients, yet mutations in severe acute respiratory syndrome coronavirus (SARS-CoV-2) variants may reduce the antibody neutralizing activity. New monoclonal antibodies (mAbs) and antibody remolding strategies are recalled in the battle with COVID-19 epidemic.<h4>Results</h4>We identified multiple mAbs from antibody phage display library made from COVID-19 patients and further characterized the R3P1-E4 clone, which effectively suppressed SARS-CoV-2 infection and rescued the lethal phenotype in mice infected with SARS-CoV-2. Crystal structural analysis not only explained why R3P1-E4 had selectively reduced binding and neutralizing activity to SARS-CoV-2 variants carrying K417 mutations,2022-01-01T00:00:00Z2022 May2026-05-31T07:09:24.737Z2025-02-19T05:05:31.65ZS-EPMC91133793558159310.1186/s13578-022-00794-7